Logo Logo
Hilfe
Hilfe
Switch Language to English

Parhofer, Klaus G. (2021): Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful? In: Current Atherosclerosis Reports, Bd. 23, Nr. 12, 74

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Purpose of Review For many years, the lipid-lowering armamentarium consisted of statins and/or ezetimibe and/or bile acid sequestrants and/or fibrates. Now, with the availability of new drugs mostly injectables, the field has changed and the role of oral non-statin drugs (including bempedoic acid) must be reevaluated. Recent Findings Ezetimibe remains a very important combination partner for statins with continuously increasing treatment numbers. Bempedoic acid is another interesting combination partner for statin/ezetimibe or ezetimibe alone but lacks in contrast to ezetimibe evidence from outcome trials. The role of fibrates is less clear as they have shown disappointing results in outcome trials but may still be used in selected, high-risk patients with combined dyslipidemia. Bile acid sequestrants are now rarely used as there are stronger, better tolerable ways to lower LDL-cholesterol. With the introduction of new injectable lipid-lowering drugs, some oral drugs such as ezetimibe and bempedoic acid still have an important spot in our treatment algorithm others such as fibrates have a less clear role while again others are now rarely used.

Dokument bearbeiten Dokument bearbeiten